Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig + Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
NCT07600151Phase 2Not yet recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Dec 2026
- Primary completion
- Sep 2036
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etentamig in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07600151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600151.